222 related articles for article (PubMed ID: 7191289)
1. Characterization of a new potent heparin. 2nd communication: Chemical analysis of the carbohydrate content and determination of the biological activity of a new potent heparin preparation in vitro, using protamine neutralization and amidolytic methods for factor Xa and thrombin.
Bhargava AS; Heinick J; Günzel P
Arzneimittelforschung; 1980; 30(7):1071-4. PubMed ID: 7191289
[TBL] [Abstract][Full Text] [Related]
2. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
Tran TH; Bondeli C; Marbet GA; Duckert F
Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
[TBL] [Abstract][Full Text] [Related]
3. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.
Diness V; Ostergaard PB
Thromb Haemost; 1986 Dec; 56(3):318-22. PubMed ID: 3563964
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments.
Racanelli A; Fareed J; Walenga JM; Coyne E
Semin Thromb Hemost; 1985 Apr; 11(2):176-89. PubMed ID: 4035365
[No Abstract] [Full Text] [Related]
5. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
6. The monitoring of heparin administration by screening tests in experimental dogs.
Mischke R; Jacobs C
Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
[TBL] [Abstract][Full Text] [Related]
7. GAGs-potentiated inhibition of thrombin, factor Xa and plasmin in plasma and in a purified system containing antithrombin III - correlation with total charge density.
Cofrancesco E; Vigo A; Pogliani EM
Thromb Haemost; 1981 Dec; 46(4):749-51. PubMed ID: 6460339
[TBL] [Abstract][Full Text] [Related]
8. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation.
Massonnet-Castel S; Pelissier E; Bara L; Terrier E; Abry B; Guibourt P; Swanson J; Jaulmes B; Carpentier A; Samama M
Haemostasis; 1986; 16(2):139-46. PubMed ID: 3710291
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a new potent heparin. 7th communication: A comparative study of a new potent heparin in human after i.v. application.
Bhargava AS; Wendt H; Günzel P
Arzneimittelforschung; 1981; 31(2):386-8. PubMed ID: 7194658
[TBL] [Abstract][Full Text] [Related]
10. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a new potent heparin. 1 communication: Determinations of anticoagulant activity of a high potency heparin preparation in vivo using dog as an experimental animal and in vitro using dog and human plasma.
Bhargava AS; Heinick J; Schöbel C; Günzel P
Arzneimittelforschung; 1980; 30(6):993-6. PubMed ID: 7191280
[TBL] [Abstract][Full Text] [Related]
12. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169).
Walenga JM; Fareed J; Hoppensteadt DA
Semin Thromb Hemost; 1985 Jan; 11(1):17-25. PubMed ID: 3883497
[TBL] [Abstract][Full Text] [Related]
13. An investigation of the functional role of the carboxylic groups of heparin. Affinity for antithrombin III and anti-Xa activity of selectively carboxyl esterified heparin.
Mardiguian J; Trillou M
Semin Thromb Hemost; 1985 Jan; 11(1):34-6. PubMed ID: 3975640
[No Abstract] [Full Text] [Related]
14. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
Bohner J; von Pape KW; Blaurock M
Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant properties of extracellular slime substance produced by Staphylococcus epidermidis.
Bykowska K; Ludwicka A; Wegrzynowicz Z; Lopaciuk S; Kopeć M
Thromb Haemost; 1985 Dec; 54(4):853-6. PubMed ID: 4089818
[TBL] [Abstract][Full Text] [Related]
16. Heparin assay: a comparison between titrimetric and amidolytic methods.
Nenci GG; Berrettini M; Agnelli G; Parise P
Boll Soc Ital Biol Sper; 1980 Mar; 56(5):519-25. PubMed ID: 7387799
[TBL] [Abstract][Full Text] [Related]
17. Effect of heparin on the neutralization of factor Xa and thrombin by the plasma alpha-2-globulin inhibitor.
Yin ET
Thromb Diath Haemorrh; 1975 Feb; 33(1):43-50. PubMed ID: 47195
[No Abstract] [Full Text] [Related]
18. Anticoagulant activity of artificial biomedical materials with co-immobilized antithrombin III and heparin.
Miura Y; Aoyagi S; Ikeda F; Miyamoto K
Biochimie; 1980; 62(8-9):595-601. PubMed ID: 7417594
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a new potent heparin. 6th communication: The comparison of the anticoagulant effect of the sodium and calcium salts of a new potent heparin after s.c. injection in beagle dogs.
Bhargava AS; Schöbel C; Günzel P
Arzneimittelforschung; 1981; 31(1):79-82. PubMed ID: 7194097
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacology of heparin].
Hoffmann A; Markwardt F
Z Gesamte Inn Med; 1979 Jan; 34(1):3-8. PubMed ID: 373277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
